Literature DB >> 21095077

Pharmacological blockade or genetic knockout of the NOP receptor potentiates the rewarding effect of morphine in rats.

Kris Rutten1, Jean De Vry, Walter Bruckmann, Thomas M Tzschentke.   

Abstract

The Nociceptin/OrphaninFQ (NOP) system is believed to be involved in drug abuse and addiction. We have recently demonstrated that activation of the NOP receptor, by systemic administration of the NOP receptor agonist Ro65-6570, attenuated the rewarding effect of various opioids in conditioned place preference (CPP) in rats and this attenuating effect was reversed by the NOP receptor antagonist J-113397. The present study demonstrates that co-administration of J-113397 (4.64 mg/kg, i.p.) during conditioning, facilitates morphine-induced CPP. Moreover, we found that NOP receptor knockout rats (oprl1(-/-)) are more sensitive to the rewarding effect of morphine than wildtype control rats. Thus, pharmacological or genetic inactivation of the NOP system rendered rats more susceptible to the rewarding effect of morphine. These findings support the suggestion that the endogenous NOP system attenuates the rewarding effect of opioids and therefore offers a therapeutic target for the treatment of drug abuse and addiction.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21095077     DOI: 10.1016/j.drugalcdep.2010.10.004

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  17 in total

Review 1.  Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists.

Authors:  W Schröder; D G Lambert; M C Ko; T Koch
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

Review 2.  Usefulness of knockout mice to clarify the role of the opioid system in chronic pain.

Authors:  Rafael Maldonado; Josep Eladi Baños; David Cabañero
Journal:  Br J Pharmacol       Date:  2018-01-06       Impact factor: 8.739

3.  Involvement of neuropeptide FF receptors in neuroadaptive responses to acute and chronic opiate treatments.

Authors:  K Elhabazi; J M Trigo; C Mollereau; L Moulédous; J-M Zajac; F Bihel; M Schmitt; J J Bourguignon; H Meziane; B Petit-demoulière; F Bockel; R Maldonado; F Simonin
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

4.  Effects of the NOP agonist SCH221510 on producing and attenuating reinforcing effects as measured by drug self-administration in rats.

Authors:  Devki D Sukhtankar; Carla H Lagorio; Mei-Chuan Ko
Journal:  Eur J Pharmacol       Date:  2014-10-29       Impact factor: 4.432

Review 5.  The genetics of the opioid system and specific drug addictions.

Authors:  Orna Levran; Vadim Yuferov; Mary Jeanne Kreek
Journal:  Hum Genet       Date:  2012-05-01       Impact factor: 4.132

6.  Genetic Deletion of the Nociceptin/Orphanin FQ Receptor in the Rat Confers Resilience to the Development of Drug Addiction.

Authors:  Marsida Kallupi; Giulia Scuppa; Giordano de Guglielmo; Girolamo Calò; Friedbert Weiss; Michael A Statnick; Linda M Rorick-Kehn; Roberto Ciccocioppo
Journal:  Neuropsychopharmacology       Date:  2016-08-26       Impact factor: 7.853

Review 7.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

Review 8.  Rat models of human diseases and related phenotypes: a systematic inventory of the causative genes.

Authors:  Claude Szpirer
Journal:  J Biomed Sci       Date:  2020-08-02       Impact factor: 8.410

Review 9.  Stress-related neuropeptides and addictive behaviors: beyond the usual suspects.

Authors:  Jesse R Schank; Andrey E Ryabinin; William J Giardino; Roberto Ciccocioppo; Markus Heilig
Journal:  Neuron       Date:  2012-10-04       Impact factor: 17.173

Review 10.  The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.

Authors:  Jeffrey M Witkin; Michael A Statnick; Linda M Rorick-Kehn; John E Pintar; Michael Ansonoff; Yanyun Chen; R Craig Tucker; Roberto Ciccocioppo
Journal:  Pharmacol Ther       Date:  2013-11-01       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.